Echocardiographic Imaging Challenges in Obesity: Guideline Recommendations and Limitations of Adjusting to Body Size
@JAHA_AHA@pattypellikka#EchoFirst#cardiotwitter
https://t.co/PnUL0HkbIX
Amigos del @MEF_Peru y @MartinVizcarraC, atención. Nuestro país tiene casi 70% de la población con sobrepeso y/o obesidad. Es necesario proteger todo lo avanzado en el país.
*The WATCH-DM Score* to predict incident HF in T2DM
Who should you watch for early consideration of #SGLT2i?
Thrilled to share late-breaking science at #HFSA2019, now simultaneously pub in @ADA_Journals in collab w/ @UTSWNews@MattSegar & @ambarish4786
https://t.co/TJusQt20XE
Corazón humano:”omnívoro metabólico” @Dr_Manito nos explica las fuentes de energía del corazón y el importante papel de la mitocondria. Clase de lujo en #Diabemir Cataluña @secardiologia
DOBLE aplauso del auditorio para el estudio de Sustitución de Sal realizado en Perú 🇵🇪 presentado por JJ Miranda en la Hot Line 3 de #ESCCongress en Paris. Congrats!!! 👏👏👏👏@cardiomicsclub
Diabetes and heart failure have a close metabolic interplay. Failing heart is metabolic inflexible and inefficient. Beneficial effect of SGLT2i on HF need more physiopathological research to really understand the great clinical achivements on DAPA-HF. Dr. Heymans. #ESCCongress
HFrEF treated with
SAC/VAL,⤵️in NT-proBNP was weakly yet significantly correlated with improvements in markers of cardiac volume and function at 12 months
💡The reverse cardiac remodeling may provide a mechanistic explanation for the effects of SAC/VAL in HFrEF #ESCCongress
congratulations to @JJheart_doc - PROVE-HF was one of the most relevant studies in #escongress 2019 and will IM-PROVE our knowledge about how sacubitril-valsartan benefits HFrEF patients
Congrats @JJheart_doc on mechanistic PROVE-HF! Still have very fond memories of BIDDS when we unexpectedly found the powerful prognostic value of BNP in the ICU in 2004. Thanks for the early mentorship! @MGHMedicine